OBJECTIVE: Type 1 diabetes (T1D) results from the inflammatory destruction of pancreatic β-cells. In this study, we investigated the effect of docosahexaenoic acid (DHA) supplementation on stimulated inflammatory cytokine production in white blood cells (WBC) from infants with a high genetic risk for T1D. RESEARCH DESIGN AND METHODS: This was a multicenter, two-arm, randomized, double-blind pilot trial of DHA supplementation, beginning either in the last trimester of pregnancy (41 infants) or in the first 5 months after birth (57 infants). Levels of DHA in infant and maternal red blood cell (RBC) membranes and in breast milk were analyzed by gas chromatography/mass spectrometry. Inflammatory cytokines were assayed from whole blood culture supernatants using the Luminex multiplex assay after stimulation with high dose lipopolysaccharide (LPS), 1 µg/mL. RESULTS: The levels of RBC DHA were increased by 61-100% in treated compared to control infants at ages 6-36 months. There were no statistically significant reductions in production of the inflammatory cytokines, IL-1β, TNFα, or IL-12p40 at any of the six timepoints measured. The inflammatory marker, high-sensitivity C-reactive protein (hsCRP), was significantly lower in breast-fed DHA-treated infants compared to all formula-fed infants at the age of 12 months. Three infants (two received DHA) were removed from the study as a result of developing ≥two persistently positive biochemical islet autoantibodies. CONCLUSIONS: This pilot trial showed that supplementation of infant diets with DHA is safe and fulfilled the pre-study goal of increasing infant RBC DHA levels by at least 20%. Inflammatory cytokine production was not consistently reduced.
RCT Entities:
OBJECTIVE:Type 1 diabetes (T1D) results from the inflammatory destruction of pancreatic β-cells. In this study, we investigated the effect of docosahexaenoic acid (DHA) supplementation on stimulated inflammatory cytokine production in white blood cells (WBC) from infants with a high genetic risk for T1D. RESEARCH DESIGN AND METHODS: This was a multicenter, two-arm, randomized, double-blind pilot trial of DHA supplementation, beginning either in the last trimester of pregnancy (41 infants) or in the first 5 months after birth (57 infants). Levels of DHA in infant and maternal red blood cell (RBC) membranes and in breast milk were analyzed by gas chromatography/mass spectrometry. Inflammatory cytokines were assayed from whole blood culture supernatants using the Luminex multiplex assay after stimulation with high dose lipopolysaccharide (LPS), 1 µg/mL. RESULTS: The levels of RBC DHA were increased by 61-100% in treated compared to control infants at ages 6-36 months. There were no statistically significant reductions in production of the inflammatory cytokines, IL-1β, TNFα, or IL-12p40 at any of the six timepoints measured. The inflammatory marker, high-sensitivity C-reactive protein (hsCRP), was significantly lower in breast-fed DHA-treated infants compared to all formula-fed infants at the age of 12 months. Three infants (two received DHA) were removed from the study as a result of developing ≥two persistently positive biochemical islet autoantibodies. CONCLUSIONS: This pilot trial showed that supplementation of infant diets with DHA is safe and fulfilled the pre-study goal of increasing infant RBC DHA levels by at least 20%. Inflammatory cytokine production was not consistently reduced.
Authors: Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth Journal: Diabetes Date: 1996-07 Impact factor: 9.461
Authors: H Peter Chase; Sonia Cooper; Iris Osberg; Lars C Stene; Katherine Barriga; Jill Norris; George S Eisenbarth; Marian Rewers Journal: Diabetes Date: 2004-10 Impact factor: 9.461
Authors: Jill M Norris; Xiang Yin; Molly M Lamb; Katherine Barriga; Jennifer Seifert; Michelle Hoffman; Heather D Orton; Anna E Barón; Michael Clare-Salzler; H Peter Chase; Nancy J Szabo; Henry Erlich; George S Eisenbarth; Marian Rewers Journal: JAMA Date: 2007-09-26 Impact factor: 56.272
Authors: Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: Kevin Hummel; Kim K McFann; Jaime Realsen; Laurel H Messer; Georgeanna J Klingensmith; H Peter Chase Journal: J Pediatr Date: 2012-05-12 Impact factor: 4.406
Authors: Elizabeth J Mayer-Davis; Dana Dabelea; Jamie L Crandell; Tessa Crume; Ralph B D'Agostino; Lawrence Dolan; Irena B King; Jean M Lawrence; Jill M Norris; Catherine Pihoker; Natalie The Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko Journal: Curr Diab Rep Date: 2018-08-30 Impact factor: 4.810
Authors: Ismail Syed; Maria F Rubin de Celis; James F Mohan; Pedro M Moraes-Vieira; Archana Vijayakumar; Andrew T Nelson; Dionicio Siegel; Alan Saghatelian; Diane Mathis; Barbara B Kahn Journal: J Clin Invest Date: 2019-08-05 Impact factor: 14.808
Authors: Diane K Wherrett; Jane L Chiang; Alan M Delamater; Linda A DiMeglio; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; Daniel J Lovell; Trevor J Orchard; Christopher M Ryan; Desmond A Schatz; David S Wendler; Carla J Greenbaum Journal: Diabetes Care Date: 2015-10 Impact factor: 19.112